Trial reportJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society2022
C-reactive protein (CRP) as a biomarker of pulmonary exacerbation presentation and treatment response.
Trial report in Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02781610 (Standardized Treatment of Pulmonary Exacerbations II), which is not on this map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Standardized Treatment of Pulmonary Exacerbations II (STOP2)
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.
- Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis.The Cochrane database of systematic reviews · 2025Pooled it
- Inflammatory checkpoints in amyotrophic lateral sclerosis: From biomarkers to therapeutic targets.Frontiers in immunology · 2022Pooled it
- Correlates of FEV₁ deficit in pulmonary exacerbations of cystic fibrosis and associated clinical outcomes.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2026Trial
- Preliminary Effects of Hydrogen-Oxygen Inhalation on Nodule Size, IL-6, and Neutrophils in Patients with Small Pulmonary Nodules.Drug design, development and therapy · 2026Trial
- Adjunctive Systemic Corticosteroids for Pulmonary Exacerbations of Cystic Fibrosis.Annals of the American Thoracic Society · 2024Trial
- Prevalence and Clinical Impact of Respiratory Viral Infections from the STOP2 Study of Cystic Fibrosis Pulmonary Exacerbations.Annals of the American Thoracic Society · 2024Trial
- Prognostic value of the CALLY index for predicting in-hospital mortality in community-acquired pneumonia: Results from an elderly-predominant cohort.Irish journal of medical science · 2026Article
- Association between C-reactive protein-to-platelet ratio and acute kidney injury in cardiac arrest survivors.BMC cardiovascular disorders · 2026Article
- Diagnostic value of combined detection of serum NLR and CRP for migraine patients in the attack stage: A prospective study.Journal of medical biochemistry · 2026Article
- Symptom phenotyping in people with cystic fibrosis during acute pulmonary exacerbations using machine-learning K-means clustering analysis.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2024Article
- Early identification and diagnosis, pathophysiology, and treatment of sepsis-related acute lung injury: a narrative review.Journal of thoracic disease · 2024Review
- Analysis of early warning indicators of death in patients with severe fever with thrombocytopenia syndrome.BMC infectious diseases · 2024Article
- Predicting return of lung function after a pulmonary exacerbation using the cystic fibrosis respiratory symptom diary-chronic respiratory infection symptom scale.BMC pulmonary medicine · 2024Observational
- STOP Using Corticosteroids in Cystic Fibrosis Pulmonary Exacerbations.Annals of the American Thoracic Society · 2024Article
- C-reactive protein: structure, function, regulation, and role in clinical diseases.Frontiers in immunology · 2024Review
- Analysis of the therapeutic effect and postoperative complications associated with 3-dimensional computed tomography navigation-assisted intervertebral foraminoscopic surgery in lumbar disc herniation in the elderly: a retrospective cohort study.Quantitative imaging in medicine and surgery · 2023Article
- Impact of lumacaftor/ivacaftor and tezacaftor/ivacaftor on treatment response in pulmonary exacerbations of F508del/F508del cystic fibrosis.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2023Article
- Antibiotic Therapy for Pulmonary Exacerbations in Cystic Fibrosis-A Single-Centre Prospective Observational Study.Antibiotics (Basel, Switzerland) · 2023Article
- Diagnosis and Management of Cystic Fibrosis Exacerbations.Seminars in respiratory and critical care medicine · 2023Review
- Can Identifying Pulmonary Exacerbation Phenotypes Guide New Treatment Approaches for Cystic Fibrosis?Annals of the American Thoracic Society · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 1 country.
Funding
Abstract
backgroundC-reactive protein (CRP) has been proposed as a biomarker for pulmonary exacerbation (PEx) diagnosis and treatment response. CRP >75mg/L has been associated with increased risk of PEx treatment failure. We have analyzed CRP measures as biomarkers for clinical response during the STOP2 PEx study (NCT02781610).
methodsCRP measures were collected at antimicrobial treatment start (V1), seven to 10 days later (V2), and two weeks after treatment end (V3). V1 log
resultsIn all, 951 of 982 STOP2 subjects (92.7%) had CRP measures at V1. V1 log DISCUSSION: Despite consistent trends, log
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.